CVS Health Outperforms Market in 2026 with Strong Earnings and Analyst Optimism
CVS Health (NYSE: CVS) has outperformed the S&P 500 this year, rising over 18% compared to the index's sub-13% gain. The stock is expected to rise further based on analyst forecasts; TipRanks reports a consensus price target of $114.59 per share — representing potential growth of nearly 22%. This optimism stems from CVS' consistent outperformance in earnings, with strong results across three quarters this year and raised guidance for both revenue and profitability. A key driver has been the healthcare benefits segment, particularly Aetna's improved medical benefit ratio (MBR), which dropped to 84.6% in Q1 of 2026 from a high of 94.8%. This improvement significantly boosted adjusted operating income for that segment by over $3 billion year-over-year and continued into the second quarter with an increase of nearly 85%. Analysts, including UBS' Kevin Caliendo, remain bullish despite operational challenges at its PBM division. CVS is also benefiting from demographic trends in aging populations increasing demand for healthcare services. With a current price around $92.90 and strong buy ratings from most analysts tracking the stock (16 out of 17), CVS appears well-positioned to continue delivering returns.
Tickers: $CVS
Topics: CVS Health financial performance healthcare pharmacy